Literature DB >> 22565849

Imaging of protein synthesis: in vitro and in vivo evaluation of (44)Sc-DOTA-puromycin.

Sebastian Eigner1, Denis R Beckford Vera, Marco Fellner, Natalia S Loktionova, Markus Piel, Ondrej Lebeda, Frank Rösch, Tobias L Roß, Katerina Eigner Henke.   

Abstract

PURPOSE: The purpose of this study was to investigate whether (44)Sc-labeled puromycin can be utilized for imaging of protein synthesis in vivo.
METHODS: For micro-positron emission tomographic (μPET) studies, 20-25 MBq of [(44)Sc]-DOTA-puromycin was administered to tumor-bearing rats, and animals were scanned for 1 h dynamically. Results were further validated by dissecting organs and tissues of the animals after the measurement and in vitro blocking experiments using puromycin or cycloheximide to block protein synthesis.
RESULTS: μPET images of tumor-bearing rats showed significant tumor uptake of [(44)Sc]-DOTA-puromycin and a clear-cut tumor visualization. In both blocking experiments, cellular uptake of [(44)Sc]-DOTA-puromycin ([(44)Sc]-DOTA-Pur) could be suppressed by blocking protein synthesis.
CONCLUSIONS: We report for the first time successful μPET imaging with (44)Sc obtained from a (44)Ti/(44)Sc generator, as well as noninvasive μPET imaging of ribosomal activity, respectively protein synthesis, with a puromycin-based radiopharmaceutical and the direct correlation between cellular uptake of [(44)Sc]-DOTA-Pur and protein synthesis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22565849     DOI: 10.1007/s11307-012-0561-3

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  12 in total

1.  PUROMYCIN INHIBITION OF PROTEIN SYNTHESIS: INCORPORATION OF PUROMYCIN INTO PEPTIDE CHAINS.

Authors:  D NATHANS
Journal:  Proc Natl Acad Sci U S A       Date:  1964-04       Impact factor: 11.205

2.  68Ga-labelled DOTA-derivatised peptide ligands.

Authors:  G-J Meyer; H Mäcke; J Schuhmacher; W H Knapp; M Hofmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-03-17       Impact factor: 9.236

3.  Post-elution processing of (44)Ti/(44)Sc generator-derived (44)Sc for clinical application.

Authors:  M Pruszyński; N S Loktionova; D V Filosofov; F Rösch
Journal:  Appl Radiat Isot       Date:  2010-04-24       Impact factor: 1.513

4.  INHIBITION BY PUROMYCIN OF AMINO ACID INCORPORATION INTO PROTEIN.

Authors:  M B Yarmolinsky; G L Haba
Journal:  Proc Natl Acad Sci U S A       Date:  1959-12       Impact factor: 11.205

5.  Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer.

Authors:  Catherine A Foss; Ronnie C Mease; Hong Fan; Yuchuan Wang; Hayden T Ravert; Robert F Dannals; Rafal T Olszewski; Warren D Heston; Alan P Kozikowski; Martin G Pomper
Journal:  Clin Cancer Res       Date:  2005-06-01       Impact factor: 12.531

6.  Specific bonding of puromycin to full-length protein at the C-terminus.

Authors:  E Miyamoto-Sato; N Nemoto; K Kobayashi; H Yanagawa
Journal:  Nucleic Acids Res       Date:  2000-03-01       Impact factor: 16.971

7.  Gallium-67/gallium-68-[DFO]-octreotide--a potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: synthesis and radiolabeling in vitro and preliminary in vivo studies.

Authors:  P M Smith-Jones; B Stolz; C Bruns; R Albert; H W Reist; R Fridrich; H R Mäcke
Journal:  J Nucl Med       Date:  1994-02       Impact factor: 10.057

8.  Puromycin oligonucleotides reveal steric restrictions for ribosome entry and multiple modes of translation inhibition.

Authors:  Shelley R Starck; Richard W Roberts
Journal:  RNA       Date:  2002-07       Impact factor: 4.942

9.  68Ga-labeled oligonucleotides for in vivo imaging with PET.

Authors:  Anne Roivainen; Tuula Tolvanen; Satu Salomäki; Gabor Lendvai; Irina Velikyan; Petri Numminen; Maria Välilä; Hannu Sipilä; Mats Bergström; Pirkko Härkönen; Harri Lönnberg; Bengt Långström
Journal:  J Nucl Med       Date:  2004-02       Impact factor: 10.057

Review 10.  Molecular imaging: what can be used today.

Authors:  P L Jager; M A de Korte; M N Lub-de Hooge; A van Waarde; K P Koopmans; P J Perik; E G E de Vries
Journal:  Cancer Imaging       Date:  2005-11-23       Impact factor: 3.909

View more
  6 in total

1.  Radiosynthesis of Carbon-11 Labeled Puromycin as a Potential PET Candidate for Imaging Protein Synthesis in Vivo.

Authors:  Selena Milicevic Sephton; Franklin I Aigbirhio
Journal:  ACS Med Chem Lett       Date:  2016-04-12       Impact factor: 4.345

2.  Matching the decay half-life with the biological half-life: ImmunoPET imaging with (44)Sc-labeled cetuximab Fab fragment.

Authors:  Rubel Chakravarty; Shreya Goel; Hector F Valdovinos; Reinier Hernandez; Hao Hong; Robert J Nickles; Weibo Cai
Journal:  Bioconjug Chem       Date:  2014-11-24       Impact factor: 4.774

3.  44Sc for labeling of DOTA- and NODAGA-functionalized peptides: preclinical in vitro and in vivo investigations.

Authors:  Katharina A Domnanich; Cristina Müller; Renata Farkas; Raffaella M Schmid; Bernard Ponsard; Roger Schibli; Andreas Türler; Nicholas P van der Meulen
Journal:  EJNMMI Radiopharm Chem       Date:  2016-05-05

Review 4.  The science of puromycin: From studies of ribosome function to applications in biotechnology.

Authors:  Ranen Aviner
Journal:  Comput Struct Biotechnol J       Date:  2020-04-24       Impact factor: 7.271

5.  Folate-based radiotracers for PET imaging--update and perspectives.

Authors:  Cristina Müller
Journal:  Molecules       Date:  2013-04-29       Impact factor: 4.411

Review 6.  Production of scandium radionuclides for theranostic applications: towards standardization of quality requirements.

Authors:  R Mikolajczak; S Huclier-Markai; C Alliot; F Haddad; D Szikra; V Forgacs; P Garnuszek
Journal:  EJNMMI Radiopharm Chem       Date:  2021-05-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.